Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

July 24th 2023

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Rini Expands on Key Clinical Trial Updates in GU Cancers from the 2023 ASCO Annual Meeting

July 20th 2023

Brian I. Rini, MD, FASCO, highlights key clinical trial updates from the genitourinary cancers landscape presented at the 2023 ASCO Annual Meeting, details the implications of the CONTACT-03 data, expands on the long-term data from the phase 3 KEYNOTE-426 trial in clear cell RCC, discusses findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer, and more.

Dr Signoretti on the Development of Novel Biomarkers in RCC Using Tissue-Based Analyses

July 19th 2023

Sabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.

Dr Hannan on the Advantages of Stereotactic Radiation in Primary and Locally Advanced RCC

July 19th 2023

Raquibul Hannan, MD, PhD, discusses the advantages of stereotactic radiation in primary or locally advanced renal cell carcinoma.

Dr Ged on the Background of the ORCHID Trial in BAP1-Mutated Metastatic RCC

July 18th 2023

Yasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.

Dr Zhang on the Potential Use of RNA Sequencing to Improve Treatment Selection in Advanced RCC

July 18th 2023

Tian Zhang, MD, MHS, discusses whether the use of RNA sequencing to identify biologic cluster assignment could improve first-line treatment selection in metastatic renal cell carcinoma.

Dr Sun on the Relationship Between Clonal Hematopoiesis and Cardiovascular Disease in RCC

July 18th 2023

Maxine Sun, PhD, MPH, discusses the association between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17th 2023

Patients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic renal cell carcinoma.

Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies

July 17th 2023

Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.

Second-Line Treatment Armamentarium in Clear Cell RCC

July 17th 2023

Comprehensive insight to treatment options available in the second-line setting of advanced clear cell renal cell carcinoma.

ADCs and Radiotherapeutics Represent Novel Treatment Methods in RCC

July 15th 2023

The investigation of treatment regimens featuring antibody-drug conjugates or radiotherapeutics are part of the ongoing wave of research in renal cell carcinoma.

Dr Basin on the Methods for Investigating Hsp70 Inhibition in Belzutifan-resistant in RCC

July 14th 2023

Michael Basin, MD, discusses the design of a preclinical investigation into the pharmacological inhibition of the molecular chaperone Hsp70 and how it relates to belzutifan resistance in clear cell renal cell carcinoma.

Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups

July 14th 2023

The combination of lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic renal cell carcinoma, including in subsets of patients who had received or were naïve to checkpoint inhibitors.

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14th 2023

Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma.

Olaparib Monotherapy Showcases Antitumor Activity in BAP1-mutated RCC

July 14th 2023

Olaparib monotherapy elicited responses with favorable tolerability in patients with renal cell carcinoma whose tumors harbored BAP1 or other DNA repair gene mutations, according to data from the interim analysis of the phase 2 ORCHID trial presented during the 2023 Kidney Cancer Research Summit.

Knowledge Gap Remains for Sequencing of Later-Line Treatments of Advanced RCC

July 14th 2023

Although the use of immunotherapy treatment approaches continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents are limited.

Leveraging Biology to Guide First-Line Treatment of Clear Cell RCC

July 14th 2023

Determining the appropriate front-line treatment pathway for patients with clear cell renal cell carcinoma may not always align with risk stratification features.

Dr Lee on Extended Follow-Up With Pembrolizumab and Lenvatinib in Pretreated mRCC

July 14th 2023

Chung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.

Dr Ged on Interim Data With Olaparib in DNA Repair Gene–Mutated mRCC

July 14th 2023

Yasser Mohamed Ali Ged, MBBS, discusses the phase 2 ORCHID trial (NCT03786796).

Dr Choueiri on Trials in Progress in Advanced Renal Cell Carcinoma

July 14th 2023

Toni K. Choueiri, MD, discusses ongoing trials in advanced renal cell carcinoma.